Blood Test Accurately Detects Alzheimer's Brain Changes Even With Other Dementias

A groundbreaking study reveals that a blood test measuring pTau217 protein can accurately detect Alzheimer's disease brain pathology even when other dementia types are present, offering hope for better diagnosis and treatment of complex brain disorders.

Researchers from Massachusetts General Hospital analyzed blood samples and brain autopsy data from 187 participants who had died and undergone brain examination. They measured three blood proteins - pTau217, GFAP, and neurofilament light chain - and compared levels to actual brain pathology found during autopsy.

The results showed pTau217 blood levels precisely reflected the severity of Alzheimer's brain changes, increasing stepwise with disease progression. Remarkably, even among people diagnosed with non-Alzheimer's dementias, those with elevated pTau217 actually had significant Alzheimer's pathology in their brains. In contrast, GFAP and NfL markers were less specific and often elevated in people without Alzheimer's changes.

This finding has profound implications for brain health and longevity. Many people develop mixed pathologies as they age, with Alzheimer's changes co-existing alongside other brain diseases. The pTau217 test could help doctors identify these complex cases earlier, potentially leading to more targeted treatments that address multiple disease processes simultaneously.

The study suggests that a positive pTau217 test shouldn't be dismissed as a false positive in someone with suspected non-Alzheimer's dementia, but rather recognized as evidence of important co-existing Alzheimer's pathology that may require specific interventions for optimal brain health preservation.